Crispr Therapeutics shares tumble after significant earnings miss
Clearway Energy (NYSE:CWENa) Inc Class C stock reached a significant milestone, hitting a 52-week high of 32.9 USD, with a substantial 26.49% gain over the past six months. According to InvestingPro data, analysts have set price targets ranging from $34 to $39, suggesting potential further upside. This marks a notable achievement for the company, reflecting positive investor sentiment and strong market performance over the past year. The stock has seen a remarkable 1-year change, increasing by 28.93%, supported by a healthy 9.08% revenue growth and an attractive 5.42% dividend yield. However, InvestingPro’s Fair Value analysis suggests the stock may be currently overvalued. For deeper insights into Clearway Energy’s valuation and 12 additional exclusive ProTips, explore the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Clearway Energy Inc. reported its first-quarter 2025 earnings, achieving an earnings per share (EPS) of $0.03, which exceeded analysts’ expectations of a $0.28 loss. Despite this positive earnings surprise, the company’s revenue of $298 million fell short of the anticipated $305.74 million. The company continues to advance its battery storage and repowering projects, with a strong outlook for 2025, focusing on renewable energy growth. Clearway Energy maintains its cash available for distribution (CAFD) guidance range of $400 to $440 million for 2025. The company has also signed a binding agreement to acquire an operational solar project in California, demonstrating its strategy to enhance its asset base. Additionally, Clearway Energy closed the acquisition of the Tuolumne Wind project, further expanding its portfolio. Analyst discussions during the earnings call highlighted the company’s confidence in its strategic initiatives, despite potential supply chain disruptions and tariff challenges. The company remains optimistic about its future projects and growth prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.